Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T85042
|
|||||
| Target Name |
Peroxisome proliferator-activated receptor (PPAR)
|
|||||
| Gene Name |
NO-GeName
|
|||||
| Target Type |
Clinical trial target
|
[1] | ||||
| Disease | [+] 1 Target-related Diseases | + | ||||
| 1 | Non-alcoholic fatty liver disease [ICD-11: DB92] | |||||
| UniProt ID | ||||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Clinical Trial Drug(s) | [+] 3 Clinical Trial Drugs | + | ||||
| 1 | A278 | Drug Info | IND submitted | Non-alcoholic steatohepatitis | [2] | |
| 2 | IVA337 | Drug Info | Phase 2 | Non-alcoholic steatohepatitis | [3] | |
| 3 | ABTL0812 | Drug Info | Phase 1/2 | Pancreatic cancer | [4] | |
| Mode of Action | [+] 1 Modes of Action | + | ||||
| Agonist | [+] 2 Agonist drugs | + | ||||
| 1 | IVA337 | Drug Info | [1] | |||
| 2 | ABTL0812 | Drug Info | [5] | |||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension. Ann Rheum Dis. 2017 Nov;76(11):1931-1940. | |||||
| REF 2 | Clinical pipeline report, company report or official report of Klus Pharma | |||||
| REF 3 | ClinicalTrials.gov (NCT03008070) Phase 2b Study in NASH to Assess IVA337 (NATIVE). U.S. National Institutes of Health. | |||||
| REF 4 | ClinicalTrials.gov (NCT04431258) A Phase I Open Label Followed by a Phase II Randomized, Controlled Study to Assess the Efficacy and Safety of ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic. U.S.National Institutes of Health. | |||||
| REF 5 | The anti-cancer drug ABTL0812 induces ER stress-mediated cytotoxic autophagy by increasing dihydroceramide levels in cancer cells. Autophagy. 2021 Jun;17(6):1349-1366. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.